Hims & Hers Health, Inc. Class A Common Stock (HIMS)
23.84
+0.00 (0.00%)
NYSE · Last Trade: Mar 13th, 7:51 AM EDT
Detailed Quote
Previous Close
23.84
Open
-
Bid
24.30
Ask
24.35
Day's Range
N/A - N/A
52 Week Range
13.74 - 70.43
Volume
283,352
Market Cap
4.58B
PE Ratio (TTM)
46.75
EPS (TTM)
0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
46,842,232
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers Health (NYSE: HIMS), a company that has navigated a volatile journey from a telehealth disruptor to a central pillar of the modern [...]
HIMS stock jumps in Thursday premarket. Explore how the Novo Nordisk partnership and a 46% short float are driving Hims & Hers Health Inc (NYSE: HIMS) higher.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant Novo Nordisk (NYSE: NVO). The deal, which effectively ends a high-stakes patent dispute, has propelled HIMS shares to record highs, closing the
Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents.
Hims & Hers Health has gotten torched over the last six months - since September 2025, its stock price has dropped 55.2% to $23.21 per share. This may have i...
Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company’s expansive vision for the future.
As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a "wellness-lite" platform for hair loss and erectile dysfunction, Hims & Hers has evolved into a diversified healthcare titan. Today, the company finds itself [...]
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from Prenuvo and adaptive bed systems from Eight Sleep. This is just the beginning of a larger benefits program that will make comprehensive, holistic care more accessible and affordable for subscribers.
The financial landscape on March 9, 2026, has reached a critical tipping point, marking one of the most aggressive sector rotations in modern market history. As technology-heavy indices struggle to find their footing under the weight of "AI fatigue" and new trade pressures, investors have staged a massive exodus into
As pharmaceutical companies race to develop treatments for metabolic dysfunction–associated steatohepatitis (MASH) and related steatotic liver disease (SLD), one critical piece of the healthcare puzzle is drawing increasing attention: how to diagnose and monitor millions of patients at scale . While most investor focus remains on drug developers, ENDRA Life Sciences (NASDAQ: NDRA) is positioning itself on the infrastructure side of the emerging MASH ecosystem with its innovative TAEUS® (Thermo-Acoustic Enhanced UltraSound) liver imaging technology.
